Radisys Announces Availability of Industry-first Release 17 Compliant 5G NR Solution
22.2.2023 16:00:00 EET | Business Wire | Press release
Radisys® Corporation, a global leader of open telecom solutions, today announced its Release 17 compliant 5G NR software solution, extending its award-winning Release 16 Software with advanced features like non-terrestrial networks (NTN) and integrated access and backhaul (IAB) that expands coverage ability for 5G Networks. Release 17 relay node and satellite access capabilities will improve worldwide cellular service availability by enhancing the accessibility of fast and reliable 5G connectivity for unserved and underserved areas. In addition to driving ubiquitous 5G consumer access, Radisys’ Release 17 compliant 5G NR software supports enterprise, infrastructure and public safety use cases including intelligent transportation systems (ITS), aeronautic broadband, maritime, critical communications, fleet management, smart factories, and Internet of Things (IoT) devices.
Radisys’ Connect RAN 5G solution facilitates a flexible 5G network to meet varied deployment requirements and provide universal 5G connectivity for diverse applications and use cases. By deploying Connect RAN 5G software, customers can minimize their development costs and operational and capital expenses while at the same time improving time-to-market and shortening their return on investment.
News Highlights
- Radisys’ Release 17 compliant RAN software continues its proven track record of 5G R&D innovation, enabling 5G Network connectivity for diverse service enabler ultra-reliable low latency communication (URLLC), and eMBB use cases across a wide set of FR1and FR2 bands for multiple deployment and access options.
- Radisys’ Connect RAN 5G software’s NTN feature supports geostationary, medium and low earth orbit (GEO/MEO/LEO) satellite access with flexible and scalable software architecture and well-defined interfaces to SATCOM infrastructure. Radisys’ NTN software empowers OEMs and ODMs to unlock newer business opportunities by leveraging the significant investment being made in SATCOM technology.
- Radisys’ IAB feature enhances centralized (CU) and distributed (DU) units to service relay nodes as 3GPP compliant Donor CUs and Donor DUs. It also includes IAB/Relay node comprising IAB-DU and IAB-MT software that provides end-to-end IAB solution integration with industry-leading platforms.
- Radisys’ Release 17 compliant RAN software provides a foundation for features such as NR positioning, reduced capability (RedCap), and NR SideLink enabling OEMs, ODMs and operators to cost-effectively scale their 5G networks.
“We are excited to launch the first-to-market Release 17 Connect RAN 5G Software delivering expanded 5G connectivity and service accessibility, enabling our customers to unlock newer business opportunities,” said Munish Chhabra, SVP and General Manager, Software and Services, Radisys. “With advanced features like NTN and IAB, Radisys continues to be a leader in delivering ORAN-compliant multi-architecture and multi-platform 5G software to our customers, driving business use cases across a variety of industry verticals.”
Meet with Radisys at MWC Barcelona
See demonstrations of Radisys’ industry-first Release 17 compliant 5G NR Solution, at MWC Barcelona, Stand 5B81. To schedule a meeting with Radisys’ mobility experts, contact open@radisys.com.
About Radisys
Radisys is a global leader in open telecom solutions and services. Its disaggregated platforms and integration services leverage open reference architectures and standards combined with open software and hardware, enabling service providers to drive open digital transformation. Radisys offers an end-to-end solutions portfolio from digital end points, to disaggregated and open access and core solutions, to immersive digital applications and engagement platforms. Its world-class and experienced network services organization delivers full lifecycle services to help service providers build and operate highly scalable and high-performance networks at optimum total cost of ownership. For more information, visit www.Radisys.com.
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005290/en/
Contact information
Nereus for Radisys
Matt Baxter, +1-503-619-0505
radisys@nereus-worldwide.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ryan Expands UK Business Rates and Property Tax Capabilities with Acquisition of WYM Rating5.2.2026 10:00:00 EET | Press release
Ryan, a leading global tax services and software provider, is pleased to announce the acquisition of Williams Young McKaig Ltd, a specialized commercial property consultancy, and its specialist rating division, WYM Rating, based in Edinburgh. The acquisition establishes Ryan’s property tax and business rates presence in Scotland and expands the Firm’s ability to serve clients with complex commercial property portfolios across the United Kingdom. Founded in 2012 by Richard Williams, Don Young, and Billy McKaig, WYM Rating is recognized for its client-centered approach and deep expertise across commercial property advisory. The consultancy supports landlords, occupiers, and investors through practical, market-informed advice grounded in decades of hands-on experience. WYM Rating’s capabilities span three focus areas, closely aligning with Ryan’s capabilities: Business rates and property tax Commercial property advisory Occupier and lease advisory “WYM Rating brings exactly the kind of sp
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 08:30:00 EET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe ® Launches LeukoStrat ® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 07:30:00 EET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 02:00:00 EET | Press release
VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise Reduction (CNR) and radial Lens Shading Correction (LSC), and featu
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 23:30:00 EET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom